Mission Statement, Vision, & Core Values (2026) of Otsuka Holdings Co., Ltd.

Founded in 1921, Otsuka Holdings Co., Ltd. (4578.T) has grown into a global healthcare player present in over 30 countries, driven by a corporate philosophy of 'Otsuka-people creating new products for better health worldwide' and a mission to be an indispensable contributor to people's health through integrated pharmaceutical and nutraceutical offerings; the company's vision to become 'The Best Partner in Clinical Nutrition Worldwide' is reinforced by leadership in intravenous solutions-holding a majority market share in Japan-and guided by core values Ryukan-godo (by sweat we recognize the way), Jissho (actualization), and Sozosei (creativity) that shape a dynamic culture focused on innovation, community harmony, and sustainable growth.

Otsuka Holdings Co., Ltd. (4578.T) - Intro

• Founded: 1921
• Global footprint: >30 countries
• Employees: ~45,000 (global)
• Ticker: 4578.T (Tokyo Stock Exchange)

• Core statement: "Otsuka-people creating new products for better health worldwide."
• Mission focus: develop differentiated pharmaceuticals and evidence-driven nutraceuticals that address unmet medical and wellness needs.
• Strategic orientation: balance between innovative R&D and scalable consumer health businesses to sustain long-term contributions to global health.

• Vision: Be an indispensable contributor to global health by delivering products that materially improve patient outcomes and everyday wellness.
• Growth priorities: specialty pharmaceuticals (CNS, oncology, rare diseases), value-added nutritionals, and expansion in emerging markets.
• Sustainability and community: pursue harmonious coexistence with local communities and the environment while maintaining dynamic corporate culture.

• Ryukan-godo - "by sweat we recognize the way" (emphasis on diligence and hands-on effort)
• Jissho - "actualization" (turning ideas into tangible patient and consumer benefits)
• Sozosei - "creativity" (continuous pursuit of novel solutions and products)

• R&D investment: prioritized in specialty drug development and novel modalities (sustained multi-year investment in clinical pipelines and collaborations).
• Portfolio balance: combination of prescription revenue streams with resilient consumer-beverage and nutraceutical cash flows to support innovation cycles.
• Community & environment: local manufacturing and CSR projects that reflect the "harmonious coexistence" commitment; sustainability reporting and targets are integrated into annual disclosures.

• Resilience: diversified revenue base reduces exposure to single-product risk while enabling long-term R&D funding.
• Innovation-led growth: core values (Ryukan-godo, Jissho, Sozosei) drive a culture that prioritizes translation of science to marketable health solutions.
• Local-global balance: the firm's emphasis on community relations and environmental stewardship supports license-to-operate in multiple jurisdictions.

Otsuka Holdings Co., Ltd. (4578.T) - Overview

• Mission statement: To be an indispensable contributor to people's health worldwide - delivering solutions across diagnosis, treatment, and daily well-being.
• Strategic pillars: Pharmaceutical innovation (prescription therapeutics and diagnostics) and nutraceuticals (everyday health-support products).
• Cultural commitments: Foster a dynamic, collaborative corporate culture and pursue harmony with the environment in R&D, production, and distribution.

• Pharmaceutical business: Focus on specialty therapeutics, psychiatric and neurological treatments, oncology, and diagnostics - investing R&D capital to advance pipeline candidates from early discovery to clinic.
• Nutraceutical business: Development and distribution of functional foods and beverages for daily health maintenance, leveraging consumer brands and global supply chains.
• Sustainability and ESG: Initiatives to reduce environmental footprint in manufacturing, promote responsible sourcing, and align governance with long-term health outcomes.

• R&D intensity supports mission-driven innovation with a multi-year pipeline funding model (~8-9% of revenue).
• Workforce and global reach enable both local-market nutraceutical distribution and international clinical development.
• Capital allocation balances growth in high-margin pharmaceuticals and steady nutraceutical cash flows to sustain long-term mission delivery.

Otsuka Holdings Co., Ltd. (4578.T) - Mission Statement

• Primary mission: deliver clinically proven nutrition and therapeutic solutions that address critical patient needs.
• Operational focus: dominate clinical IV solutions in Japan while expanding global clinical nutrition footprint.
• Business purpose: align commercial success with measurable health outcomes and innovation investment.

• Market leadership in Japan: Otsuka holds a majority share (>50%) of the packaged intravenous clinical nutrition and related IV solution market, underpinning its domestic leadership.
• Global expansion: the company operates in multiple regions with manufacturing, R&D, and distribution in Asia, North America, Europe, and other markets to deliver clinical nutrition worldwide.
• R&D and innovation: sustained investment in clinical research and formulation development to strengthen product pipelines and improve patient outcomes.
• Trusted healthcare partner: long-term contracts and partnerships with hospitals, medical distributors, and government procurement systems.

• Clinical focus: prioritize product lines that provide immediate clinical benefit (IV fluids, clinical nutrition formulations, hospital-use therapeutics).
• Supply reliability: secure manufacturing capacity and logistics to ensure uninterrupted hospital supply chains.
• Evidence generation: grow clinical evidence and real-world data to demonstrate efficacy, safety, and cost-effectiveness.
• Strategic partnerships: engage healthcare systems, procurement bodies, and academic institutions to scale access.

• Patients and providers: prioritize product quality, safety, and evidence-based benefits for vulnerable patient populations requiring clinical nutrition.
• Employees: build specialized clinical, regulatory, and manufacturing capabilities to sustain mission delivery.
• Investors: translate clinical leadership into sustainable revenue growth and resilient margins through premium, hospital-facing product lines.

Otsuka Holdings Co., Ltd. (4578.T) Vision Statement

• Emphasis on global health: expanding access to psychiatric, oncology and specialty therapies while scaling nutrition products (electrolyte beverages, medical nutrition) in emerging markets.
• Integration of sustainability: manufacturing and supply-chain targets that aim to reduce environmental footprint and promote circular practices across subsidiaries.
• Investment-led growth: prioritizing R&D and strategic M&A to convert scientific discovery into patient- and consumer-facing solutions.

• Ryukan-godo (by sweat we recognize the way) - a work ethic-driven commitment to perseverance and hands-on problem solving that underpins operations and product development.
• Jissho (actualization) - translating research and corporate intent into tangible products, services and measurable outcomes for patients and consumers.
• Sozosei (creativity) - fostering inventive approaches across science, marketing and business models to develop differentiated solutions.

• Innovation pipeline: R&D decisions prioritize projects that marry creativity (Sozosei) with real-world applicability (Jissho), supported by disciplined execution (Ryukan-godo).
• Corporate culture: cross-functional teams, lab-to-market pathways and incentives that reward persistent problem-solving and novel thinking.
• Environmental harmony: product life-cycle thinking and sustainability KPIs are embedded in project approval and manufacturing processes.

• Resource allocation: significant R&D spend sustains a pipeline where Jissho and Sozosei convert scientific assets into marketable therapies and nutrition products.
• Global reach: ~47,000 employees and a diversified business mix balance risk across geographies and product categories, enabling sustained investment in innovation.
• Sustainability linkage: operational KPIs and capital expenditure plans reflect a drive to harmonize production growth with environmental stewardship.

• Product innovation - Pocari Sweat and other consumer health brands use iterative creative development (Sozosei) and disciplined market rollouts (Jissho).
• Pharmaceutical pipeline - investment in psychiatric and oncology R&D showing the Ryukan-godo ethos through long-term clinical development commitments.
• Corporate initiatives - sustainability targets and cross-border partnerships that align commercial scale with environmental and social responsibility.